These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14742224)

  • 1. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
    Launay O; Tod M; Louchahi K; Belarbi L; Bouchaud O; Mémain N; Petitjean O; Robineau M; Guillevin L; Lortholary O
    Antimicrob Agents Chemother; 2004 Feb; 48(2):632-4. PubMed ID: 14742224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
    Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
    J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.
    Antoniou T; Tseng AL; van Heeswijk RP; Walker SE; Giguere P; Phillips EJ
    Ther Drug Monit; 2005 Dec; 27(6):779-81. PubMed ID: 16306854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
    Dicenzo R; Luque A; Larppanichpoonphol P; Reichman R
    J Antimicrob Chemother; 2006 Aug; 58(2):393-400. PubMed ID: 16760191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography.
    Ray J; Pang E; Carey D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Aug; 775(2):225-30. PubMed ID: 12113989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
    Colombo S; Buclin T; Décosterd LA; Telenti A; Furrer H; Lee BL; Biollaz J; Eap CB;
    Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
    Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
    HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy.
    Debiaggi M; Zara F; Spinillo A; De Santolo A; Maserati R; Bruno R; Sacchi P; Achilli G; Pistorio A; Romero E; Filice G
    Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):91-6. PubMed ID: 11305478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.
    Pawiński T; Pulik P; Gralak B; Horban A
    Acta Pol Pharm; 2008; 65(1):93-100. PubMed ID: 18536180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Verweel G; Wynne LH; Winchell GA; Leavitt RY; Nguyen BY; de Groot R; Burger DM
    Antimicrob Agents Chemother; 2004 May; 48(5):1904-7. PubMed ID: 15105157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Kuschak D; Mauss S; Schmutz G; Gantke B
    Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study.
    Elzi L; Hirsch HH; Battegay M
    AIDS; 2006 Jan; 20(1):129-31. PubMed ID: 16327333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.
    Lee LS; Panchalingam A; Yap MC; Paton NI
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4476-8. PubMed ID: 15504888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
    Keil K; Frerichs VA; DiFrancesco R; Morse G
    Ther Drug Monit; 2003 Jun; 25(3):340-6. PubMed ID: 12766563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.